



For Immediate Release

Contact: Pauline T. Mayer
PTM Healthcare Marketing, Inc.
631.979.3780 or PTM@ptmhcm.com

EKOS Corporation Supports Educational Session at C 3

BOTHELL, WA: June 1, 2009: EKOS Corporation is supporting a special session at the C 3, Capital Cardiovascular Conference (Baltimore, MD) on Monday, 6:30 p.m., June 15 entitled, “Venous Thromboembolic Disease Management for the Advanced Interventionalist: Expanding Your Practice with Deep Venous Thrombosis (DVT) Intervention.

Robert W. Hubert, President/CEO of EKOS Corporation, notes, “EKOS Corporation is pleased to provide support for the education of this undertreated disease; also an initiative of the Surgeon General.”

Peter Soukas, MD (Brighton, MA) and Frank Arko, MD (Dallas, TX) will moderate a panel of leading experts to include:

7:05 pm - 7:15 pm: Anthony Comerota, MD (Toledo, OH): Why Should We Change Our Traditional Conservative Method of Treatment and Move to more Aggressive Therapy?

7:15 pm - 7:25 pm: Frank Arko, MD: DVT Percutaneous Intervention: When and How? Therapeutic Options and Clinical Pearls

7:25 pm - 7:35 pm: Peter Soukas, MD: DVT Percutaneous Intervention: New Opportunity for Interventional Cardiologists and Reimbursement Guidelines

7:35 pm - 7:45 pm: Venkatesh Ramaiah, MD (Phoenix, AZ): IVC Filters: Types, Placement Techniques and Indications.

7:45 pm - 7:55 pm: David Deaton, MD (Washington, DC): IVC Filters: Differentiating Between

the Platforms and Pitfalls

A question and answer session will immediately follow. Attendees are invited to visit the EKOS booth # 207 where they can get firsthand knowledge of the EKOS MicroSonic™ Accelerated Thrombolysis device, the standard for treating DVT and PAO. Patients are exposed to less thrombolytic and it clears the clot more completely. With the introduction of the EkoSonic Endovascular System, it is also four times faster.¹

About EKOS Corporation: EKOS® Corporation pioneered the development and the clinical application of ultrasound enhanced drug delivery technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions across the nation use EKOS MicroSonic™ accelerated thrombolysis to provide safer, faster and more complete dissolution of thrombus. In 2008, the company introduced its 2nd generation EkoSonic™ Endovascular System with Rapid Pulse™ Modulation. The EkoSonic System is FDA cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. It is currently used to treat patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT) and additional applications are being investigated. For additional information visit EKOS on the web at www.EKOSCorp.com.

About C 3: The conference goal is to allow participants to understand the results from important clinical trials and evidence-based medicine and to use that understanding as guidance as they globally manage patients with atherosclerotic cardiovascular disease, especially as they face complex coronary, carotid, and peripheral arterial cases. For additional information visit C 3 on the web at <http://www.c3conference.net/index.php>.

¹ *In Vitro* Data on File At EKOS